Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Bisphosphonates in bone diseases
Autore:
Sparidans, RW; Twiss, IM; Talbot, S;
Indirizzi:
Leidenandsv, Med Ctr, Dept Clin Pharm & Toxicol, NL-2600 RC Leiden, Netherl Leiden Univ Leiden Netherlands NL-2600 RC ol, NL-2600 RC Leiden, Netherl
Titolo Testata:
PHARMACY WORLD & SCIENCE
fascicolo: 5, volume: 20, anno: 1998,
pagine: 206 - 213
SICI:
0928-1231(199810)20:5<206:BIBD>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
CANCER-ASSOCIATED HYPERCALCEMIA; TUMOR-INDUCED HYPERCALCEMIA; PLASMA-PROTEIN BINDING; PAGETS-DISEASE; POSTMENOPAUSAL OSTEOPOROSIS; BREAST-CANCER; INTRAVENOUS PAMIDRONATE; CLINICAL-PHARMACOLOGY; MULTIPLE-MYELOMA; DOUBLE-BLIND;
Keywords:
bisphosphonates; Paget's disease; osteoporosis; hypercalcaemia of malignancy; metastatic bone disease;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
106
Recensione:
Indirizzi per estratti:
Indirizzo: Sparidans, RW Leidenn,niv, Med Ctr, Dept Clin Pharm & Toxicol, POB 9600, NL-2600 RC Leide Leiden Univ POB 9600 Leiden Netherlands NL-2600 RC RC Leide
Citazione:
R.W. Sparidans et al., "Bisphosphonates in bone diseases", PHARM WORLD, 20(5), 1998, pp. 206-213

Abstract

Bisphosphonates are a class of drugs which are strongly attracted to the bone where they influence the calcium metabolism, mainly by inhibition of the osteoclast-mediated bone resorption. This property makes these compounds suited for the treatment of several diseases of the bone. In Paget's disease, several bisphosphonates can reduce bone pain and decrease the bone turnover 60-70%. Cyclical oral etidronate and daily oral alendronate both provedto reduce the vertebral fracture rate for bisphosphonates can increase spinal bone mass in osteoporosis. Bisphosphonates can help lowering serum calcium and reverse skeletal complications in malignancy mediated bone diseases. Oral and intravenous administration of therapeutic doses is relatively safe. In general, gastrointestinal disturbances are described most often and the oldest, least potent, bisphosphonate etidronate can induce osteomalacia. The various characteristics of bisphosphonates: physicochemical, biological, therapeutic and toxicological, vary greatly depending on the structure of the individual bisphosphonate. Even small changes in the structure can lead to enormous differences in potency. Overall, this class of drugs offersseveral prospects for the future.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 09:35:40